Handelsbanken Fonder AB Buys 28,130 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Handelsbanken Fonder increased its Zimmer Biomet stake by 22.7% in the second quarter, purchasing 28,130 shares to own 152,064 shares worth approximately $13.1 million. Institutional investors collectively hold 88.89% of the company.
• Zimmer Biomet exceeded quarterly expectations, reporting $2.07 in EPS and $2.18 billion in revenue, with revenue up 4.8% year over year. The company maintained fiscal 2026 EPS guidance of $8.47–$8.59 and pays a $0.24 quarterly dividend.
• Analyst sentiment remains mixed, with a consensus “Hold” rating and an average price target of $104.42, compared with the stock’s opening price of $99.47. Insider ownership is low at 1.28%, following an insider sale of 5,000 shares.

Handelsbanken Fonder AB lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 22.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 152,064 shares of the medical equipment provider's stock after buying an additional 28,130 shares during the period. Handelsbanken Fonder AB owned approximately 0.08% of Zimmer Biomet worth $13,091,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. PNC Financial Services Group Inc. increased its stake in shares of Zimmer Biomet by 9.4% during the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider's stock valued at $14,495,000 after buying an additional 13,883 shares during the period. Morningstar Investment Management LLC boosted its holdings in Zimmer Biomet by 235.4% in the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider's stock valued at $5,204,000 after acquiring an additional 40,610 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Zimmer Biomet by 257.2% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 34,370 shares of the medical equipment provider's stock valued at $3,091,000 after purchasing an additional 24,748 shares during the period. Robertson Stephens Wealth Management LLC bought a new position in Zimmer Biomet in the 4th quarter worth $1,131,000. Finally, CIBC Asset Management Inc lifted its position in shares of Zimmer Biomet by 67.6% in the 4th quarter. CIBC Asset Management Inc now owns 46,516 shares of the medical equipment provider's stock worth $4,183,000 after purchasing an additional 18,769 shares during the period. Institutional investors own 88.89% of the company's stock.

Insider Activity

In other news, insider Sang Yi sold 5,000 shares of the business's stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares of the company's stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Price Performance

NYSE ZBH opened at $99.47 on Friday. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29. The stock has a 50-day moving average of $91.24 and a 200 day moving average of $90.47. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market capitalization of $18.97 billion, a price-to-earnings ratio of 24.20, a PEG ratio of 3.11 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the business posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, July 31st. Stockholders of record on Thursday, June 25th were paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet's dividend payout ratio (DPR) is currently 23.36%.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of research analyst reports. Citizens Jmp lowered their target price on Zimmer Biomet from $120.00 to $105.00 and set a "market outperform" rating for the company in a research note on Wednesday, April 29th. Truist Financial boosted their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the company a "hold" rating in a report on Thursday, August 6th. Wall Street Zen downgraded shares of Zimmer Biomet from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Royal Bank Of Canada increased their price target on shares of Zimmer Biomet from $101.00 to $110.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Finally, Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of "Hold" and a consensus target price of $104.42.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source